免疫系统
免疫疗法
肠道菌群
免疫检查点
生物
肿瘤微环境
免疫学
免疫
癌症研究
作者
Juanjuan Wang,Ningning Zhu,Lei Su,Rongcun Yang
出处
期刊:Cancer Letters
[Elsevier]
日期:2023-12-07
卷期号:582: 216582-216582
被引量:5
标识
DOI:10.1016/j.canlet.2023.216582
摘要
Tumor cells can evade immune surveillance by expressing immune checkpoint molecule ligands, resulting in effective immune cell inactivation. Immune checkpoint blockades (ICBs) have dramatically improved survival of patients with multiple types of cancers. However, responses to ICB immunotherapy are heterogeneous with lower patient response rates. The advances have established that the gut microbiota can be as a promising target to overcome resistance to ICB immunotherapy. Furthermore, some bacterial species have shown to promote improved responses to ICBs. However, gut microbiota is critical in maintaining gut and systemic immune homeostasis. It not only promotes differentiation and function of immunosuppressive immune cells but also inhibits inflammatory cells via gut microbiota derived products such as short chain fatty acids (SCFAs), tryptophan (Trp) and bile acid (BA) metabolites, which play an important role in tumor immunity. Since the gut microbiota can either inhibit or enhance immune against tumor, it should be a double-edged sword in ICBs against tumor. In this review, we discuss the effects of gut microbiota on immune cells and also tumor cells, especially enhances of gut microbiota on ICB immunotherapy. These discussions can hopefully promote the development of ICB immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI